-+ 0.00%
-+ 0.00%
-+ 0.00%
Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+
Share
Listen to the news
Otsuka wins FDA approval for Simtriyo ADHD treatment in adults, children 6+
  • Otsuka won FDA clearance for SIMTRIYO (centanafadine) to treat ADHD in adults, children aged 6+ weighing at least 20 kg.
  • Drug is positioned as the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for ADHD.
  • US launch is slated for later this year, pending DEA scheduling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607242125BIZWIRE_USPR_____20260724_BW968244) on July 25, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending